Nicholas Strash
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Nicholas Strash has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Nenad Bursac
Duke University
8 shared publications - Sophia DeLuca
Department of Cell Biology, Duke University School of Medicine, Durham, NC, USA
4 shared publications - Geovanni L. Janer Carattini
Department of Genetics, Stanford University School of Medicine, Stanford, CA 94305
3 shared publications - Abbigail Helfer
Department of Biomedical Engineering Duke University Durham NC 27708 USA
2 shared publications - Jacob C. Scherba
Department of Biomedical Engineering Duke University Durham North Carolina USA
2 shared publications Marisa Patsy
Department of Biomedical Engineering Duke University Durham NC 27708 USA
2 shared publications
Latest Publications
- 5 December 2025
- Published by Wiley in Advanced Functional Materials
- Vol. 36 (27)
Crossbow Bioreactors for Studying the Effects of Time‐Varying Mechanical Preload and Afterload on Engineered Cardiac Tissues
Mechanical loading plays a critical role in heart development and function, with cardiac preload (tissue stretch during chamber filling) and afterload (resistance against which the heart works to eject blood) potentially playing distinct roles in postnatal cardiomyocyte maturation. To dissect the effects of various types of mechanical loading on postnatal cardiomyocytes, we developed a novel “crossbow” bioreactor system capable of independently and dynamically modulating preload and afterload under auxotonic conditions in 3D engineered cardiac tissues. The system employs tunable, curved polydimethylsiloxane (PDMS) cantilever arms that increase resistance to cardiac contractions as they are deflected and a ratcheted center beam to allow for control of preload via change in cardiac tissue length. Culture of cardiobundles made from neonatal rat cardiomyocytes embedded in a fibrin‐based hydrogel on the crossbow system reveals physiological, rather than pathological, responses to loading. Progressively increased afterload over 2 weeks of culture enhances cardiomyocyte contractile force, while progressively increased preload promotes cardiomyocyte elongation and cycling. The crossbow system holds potential for refining our understanding of mechanosensing in cardiac developmental and pathological remodeling, making it a promising tool for in vitro studies of cardiac biology, disease modeling, and pharmaceutical testing.
- 5 December 2025
- Published by Wiley in Advanced Functional Materials
- Vol. 36 (27)
Crossbow Bioreactors for Studying the Effects of Time‐Varying Mechanical Preload and Afterload on Engineered Cardiac Tissues
Mechanical loading plays a critical role in heart development and function, with cardiac preload (tissue stretch during chamber filling) and afterload (resistance against which the heart works to eject blood) potentially playing distinct roles in postnatal cardiomyocyte maturation. To dissect the effects of various types of mechanical loading on postnatal cardiomyocytes, we developed a novel “crossbow” bioreactor system capable of independently and dynamically modulating preload and afterload under auxotonic conditions in 3D engineered cardiac tissues. The system employs tunable, curved polydimethylsiloxane (PDMS) cantilever arms that increase resistance to cardiac contractions as they are deflected and a ratcheted center beam to allow for control of preload via change in cardiac tissue length. Culture of cardiobundles made from neonatal rat cardiomyocytes embedded in a fibrin‐based hydrogel on the crossbow system reveals physiological, rather than pathological, responses to loading. Progressively increased afterload over 2 weeks of culture enhances cardiomyocyte contractile force, while progressively increased preload promotes cardiomyocyte elongation and cycling. The crossbow system holds potential for refining our understanding of mechanosensing in cardiac developmental and pathological remodeling, making it a promising tool for in vitro studies of cardiac biology, disease modeling, and pharmaceutical testing.
- Open Access
- 2 September 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (17) , e040497
Effects of Pharmacological Polyploidization in Human iPSC‐Derived Cardiomyocytes
- 2 September 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (17) , e040497
Open AccessEffects of Pharmacological Polyploidization in Human iPSC‐Derived Cardiomyocytes
- 7 November 2024
- Published by Wiley in Advanced Healthcare Materials
- Vol. 14 (1)
Engineered Cardiac Tissues as a Platform for CRISPR‐Based Mitogen Discovery
Improved understanding of cardiomyocyte (CM) cell cycle regulation may allow researchers to stimulate pro‐regenerative effects in injured hearts or promote maturation of human stem cell‐derived CMs. Gene therapies, in particular, hold promise to induce controlled proliferation of endogenous or transplanted CMs via transient activation of mitogenic processes. Methods to identify and characterize candidate cardiac mitogens in vitro can accelerate translational efforts and contribute to the understanding of the complex regulatory landscape of CM proliferation and postnatal maturation. In this study, A CRISPR knockout‐based screening strategy using in vitro neonatal rat ventricular myocyte (NRVM) monolayers is established, followed by candidate mitogen validation in mature 3‐D engineered cardiac tissues (ECTs). This screen identified knockout of the purine metabolism enzyme adenosine deaminase (ADA‐KO) as an effective pro‐mitogenic stimulus. RNA‐sequencing of ECTs further reveals increased pentose phosphate pathway (PPP) activity as the primary driver of ADA‐KO‐induced CM cycling. Inhibition of the pathway's rate limiting enzyme, glucose‐6‐phosphate dehydrogenase (G6PD), prevented ADA‐KO induced CM cycling, while increasing PPP activity via G6PD overexpression increased CM cycling. Together, this study demonstrates the development and application of a genetic/tissue engineering platform for in vitro discovery and validation of new candidate mitogens affecting regenerative or maturation states of cardiomyocytes.
- 7 November 2024
- Published by Wiley in Advanced Healthcare Materials
- Vol. 14 (1)
Engineered Cardiac Tissues as a Platform for CRISPR‐Based Mitogen Discovery
Improved understanding of cardiomyocyte (CM) cell cycle regulation may allow researchers to stimulate pro‐regenerative effects in injured hearts or promote maturation of human stem cell‐derived CMs. Gene therapies, in particular, hold promise to induce controlled proliferation of endogenous or transplanted CMs via transient activation of mitogenic processes. Methods to identify and characterize candidate cardiac mitogens in vitro can accelerate translational efforts and contribute to the understanding of the complex regulatory landscape of CM proliferation and postnatal maturation. In this study, A CRISPR knockout‐based screening strategy using in vitro neonatal rat ventricular myocyte (NRVM) monolayers is established, followed by candidate mitogen validation in mature 3‐D engineered cardiac tissues (ECTs). This screen identified knockout of the purine metabolism enzyme adenosine deaminase (ADA‐KO) as an effective pro‐mitogenic stimulus. RNA‐sequencing of ECTs further reveals increased pentose phosphate pathway (PPP) activity as the primary driver of ADA‐KO‐induced CM cycling. Inhibition of the pathway's rate limiting enzyme, glucose‐6‐phosphate dehydrogenase (G6PD), prevented ADA‐KO induced CM cycling, while increasing PPP activity via G6PD overexpression increased CM cycling. Together, this study demonstrates the development and application of a genetic/tissue engineering platform for in vitro discovery and validation of new candidate mitogens affecting regenerative or maturation states of cardiomyocytes.
- Open Access
- 26 January 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 10 (4) , eadh2598
Time-dependent effects of BRAF-V600E on cell cycling, metabolism, and function in engineered myocardium
Candidate cardiomyocyte (CM) mitogens such as those affecting the extracellular signal–regulated kinase (ERK) signaling pathway represent potential targets for functional heart regeneration. We explored whether activating ERK via a constitutively active mutant of B-raf proto-oncogene (BRAF), BRAF-V600E (caBRAF), can induce proproliferative effects in neonatal rat engineered cardiac tissues (ECTs). Sustained CM-specific caBRAF expression induced chronic ERK activation, substantial tissue growth, deficit in sarcomeres and contractile function, and tissue stiffening, all of which persisted for at least 4 weeks of culture. caBRAF-expressing CMs in ECTs exhibited broad transcriptomic changes, shift to glycolytic metabolism, loss of connexin-43, and a promigratory phenotype. Transient, doxycycline-controlled caBRAF expression revealed that the induction of CM cycling is rapid and precedes functional decline, and the effects are reversible only with short-lived ERK activation. Together, direct activation of the BRAF kinase is sufficient to modulate CM cycling and functional phenotype, offering mechanistic insights into roles of ERK signaling in the context of cardiac development and regeneration.
- 26 January 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 10 (4) , eadh2598
Open AccessTime-dependent effects of BRAF-V600E on cell cycling, metabolism, and function in engineered myocardium
Candidate cardiomyocyte (CM) mitogens such as those affecting the extracellular signal–regulated kinase (ERK) signaling pathway represent potential targets for functional heart regeneration. We explored whether activating ERK via a constitutively active mutant of B-raf proto-oncogene (BRAF), BRAF-V600E (caBRAF), can induce proproliferative effects in neonatal rat engineered cardiac tissues (ECTs). Sustained CM-specific caBRAF expression induced chronic ERK activation, substantial tissue growth, deficit in sarcomeres and contractile function, and tissue stiffening, all of which persisted for at least 4 weeks of culture. caBRAF-expressing CMs in ECTs exhibited broad transcriptomic changes, shift to glycolytic metabolism, loss of connexin-43, and a promigratory phenotype. Transient, doxycycline-controlled caBRAF expression revealed that the induction of CM cycling is rapid and precedes functional decline, and the effects are reversible only with short-lived ERK activation. Together, direct activation of the BRAF kinase is sufficient to modulate CM cycling and functional phenotype, offering mechanistic insights into roles of ERK signaling in the context of cardiac development and regeneration.
- Open Access
BRAF-V600E-Mediated Erk Activation Promotes Sustained Cell Cycling and Broad Transcriptional Changes in Neonatal Cardiomyocytes
Mitogens capable of promoting cardiomyocyte proliferation represent important targets for functional heart regeneration following myocardial infarction. We previously described an ERK-dependent pro-proliferative tissue phenotype following overexpression of constitutively-active (ca) human ERBB2 in both neonatal rat ventricular myocytes (NRVMs) and human iPSC-derived cardiomyocytes (hiPSC-CMs). Since ERBB2 canonically regulates multiple other pathways in addition to ERK, it is unclear whether ERK activation alone can drive CM proliferation. Here, we activated ERK in a targeted fashion by CM-specific lentiviral expression of a constitutively active mutant of BRAF, BRAF-V600E (caBRAF), in cultured NRVMs and examined the effects on engineered NRVM tissue proliferation, morphology, and function. caBRAF expression induced ERK activation, tissue growth, loss of contractile function, and increased tissue stiffness, all of which were sustained for at least 4 weeks in vitro . From bulk RNA-sequencing analysis of engineered tissues, we found that caBRAF had broad transcriptomic effects on CMs and induced a shift to glycolytic metabolism. Together, this work shows that direct ERK activation is sufficient to modulate CM cycling and functional maturation in a cell-autonomous fashion and could offer a potential target for cardiac regenerative therapies.
Open AccessBRAF-V600E-Mediated Erk Activation Promotes Sustained Cell Cycling and Broad Transcriptional Changes in Neonatal Cardiomyocytes
Mitogens capable of promoting cardiomyocyte proliferation represent important targets for functional heart regeneration following myocardial infarction. We previously described an ERK-dependent pro-proliferative tissue phenotype following overexpression of constitutively-active (ca) human ERBB2 in both neonatal rat ventricular myocytes (NRVMs) and human iPSC-derived cardiomyocytes (hiPSC-CMs). Since ERBB2 canonically regulates multiple other pathways in addition to ERK, it is unclear whether ERK activation alone can drive CM proliferation. Here, we activated ERK in a targeted fashion by CM-specific lentiviral expression of a constitutively active mutant of BRAF, BRAF-V600E (caBRAF), in cultured NRVMs and examined the effects on engineered NRVM tissue proliferation, morphology, and function. caBRAF expression induced ERK activation, tissue growth, loss of contractile function, and increased tissue stiffness, all of which were sustained for at least 4 weeks in vitro . From bulk RNA-sequencing analysis of engineered tissues, we found that caBRAF had broad transcriptomic effects on CMs and induced a shift to glycolytic metabolism. Together, this work shows that direct ERK activation is sufficient to modulate CM cycling and functional maturation in a cell-autonomous fashion and could offer a potential target for cardiac regenerative therapies.
- Open Access
- 19 October 2021
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 10
Human Erbb2-induced Erk activity robustly stimulates cycling and functional remodeling of rat and human cardiomyocytes
Multiple mitogenic pathways capable of promoting mammalian cardiomyocyte (CM) proliferation have been identified as potential candidates for functional heart repair following myocardial infarction. However, it is unclear whether the effects of these mitogens are species-specific and how they directly compare in the same cardiac setting. Here, we examined how CM-specific lentiviral expression of various candidate mitogens affects human induced pluripotent stem cell-derived CMs (hiPSC-CMs) and neonatal rat ventricular myocytes (NRVMs) in vitro. In 2D-cultured CMs from both species, and in highly mature 3D-engineered cardiac tissues generated from NRVMs, a constitutively active mutant form of the human gene Erbb2 (cahErbb2) was the most potent tested mitogen. Persistent expression of cahErbb2 induced CM proliferation, sarcomere loss, and remodeling of tissue structure and function, which were attenuated by small molecule inhibitors of Erk signaling. These results suggest transient activation of Erbb2/Erk axis in CMs as a potential strategy for regenerative heart repair.
- 19 October 2021
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 10
Open AccessHuman Erbb2-induced Erk activity robustly stimulates cycling and functional remodeling of rat and human cardiomyocytes
Multiple mitogenic pathways capable of promoting mammalian cardiomyocyte (CM) proliferation have been identified as potential candidates for functional heart repair following myocardial infarction. However, it is unclear whether the effects of these mitogens are species-specific and how they directly compare in the same cardiac setting. Here, we examined how CM-specific lentiviral expression of various candidate mitogens affects human induced pluripotent stem cell-derived CMs (hiPSC-CMs) and neonatal rat ventricular myocytes (NRVMs) in vitro. In 2D-cultured CMs from both species, and in highly mature 3D-engineered cardiac tissues generated from NRVMs, a constitutively active mutant form of the human gene Erbb2 (cahErbb2) was the most potent tested mitogen. Persistent expression of cahErbb2 induced CM proliferation, sarcomere loss, and remodeling of tissue structure and function, which were attenuated by small molecule inhibitors of Erk signaling. These results suggest transient activation of Erbb2/Erk axis in CMs as a potential strategy for regenerative heart repair.
- 8 March 2021
- Published by Elsevier in Acta Biomaterialia
- Vol. 126, 144-153
Loss of sarcomeric proteins via upregulation of JAK/STAT signaling underlies interferon-γ-induced contractile deficit in engineered human myocardium
- 8 March 2021
- Published by Elsevier in Acta Biomaterialia
- Vol. 126, 144-153
Loss of sarcomeric proteins via upregulation of JAK/STAT signaling underlies interferon-γ-induced contractile deficit in engineered human myocardium
- Open Access
Human Erbb2-induced Erk Activity Robustly Stimulates Cycling and Functional Remodeling of Rat and Human Cardiomyocytes
Multiple mitogenic pathways capable of promoting mammalian cardiomyocyte (CM) proliferation have been identified as potential candidates for functional heart repair following myocardial infarction. However, it is unclear whether the effects of these mitogens are species-specific and how they directly compare in the same cardiac setting. Here, we examined how CM-specific lentiviral expression of various candidate mitogens affects human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) and neonatal rat ventricular myocytes (NRVMs) in vitro . In 2D-cultured CMs from both species, and in highly mature 3D-engineered cardiac tissues generated from NRVMs, a constitutively-active mutant form of the human gene Erbb2 (cahErbb2) was the most potent tested mitogen. Persistent expression of cahErbb2 induced CM proliferation, sarcomere loss, and remodeling of tissue structure and function, which were attenuated by small molecule inhibitors of Erk signaling. These results suggest transient activation of Erbb2/Erk axis in cardiomyocytes as a potential strategy for regenerative heart repair.
Open AccessHuman Erbb2-induced Erk Activity Robustly Stimulates Cycling and Functional Remodeling of Rat and Human Cardiomyocytes
Multiple mitogenic pathways capable of promoting mammalian cardiomyocyte (CM) proliferation have been identified as potential candidates for functional heart repair following myocardial infarction. However, it is unclear whether the effects of these mitogens are species-specific and how they directly compare in the same cardiac setting. Here, we examined how CM-specific lentiviral expression of various candidate mitogens affects human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) and neonatal rat ventricular myocytes (NRVMs) in vitro . In 2D-cultured CMs from both species, and in highly mature 3D-engineered cardiac tissues generated from NRVMs, a constitutively-active mutant form of the human gene Erbb2 (cahErbb2) was the most potent tested mitogen. Persistent expression of cahErbb2 induced CM proliferation, sarcomere loss, and remodeling of tissue structure and function, which were attenuated by small molecule inhibitors of Erk signaling. These results suggest transient activation of Erbb2/Erk axis in cardiomyocytes as a potential strategy for regenerative heart repair.